Jose Flores
Emergency Medicine · Sanger, CANPI 1700945136
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 216 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Corcept Therapeutics at 46.9% of the total. Among emergency medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 216 payments — averaging $27.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$3K
- Novo Nordisk$440
- Bayer$342
- Xeris Pharmaceuticals, Inc.$325
- Otsuka America Pharmaceutical, Inc.$274
- Lilly USA, LLC$264
- plus $2K from 22 others
What the payments were for
- Food & beverage$6,035100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 76 | $2,833 |
| Novo Nordisk | 21 | $440 |
| Bayer | 17 | $342 |
| Xeris Pharmaceuticals, Inc. | 10 | $325 |
| Otsuka America Pharmaceutical, Inc. | 8 | $274 |
| Lilly USA, LLC | 11 | $264 |
| GSK | 5 | $179 |
| Merck | 6 | $178 |
| Johnson & Johnson | 6 | $170 |
| Indivior Inc. | 6 | $132 |
| AbbVie | 1 | $124 |
| Ultragenyx Pharmaceutical Inc. | 6 | $121 |
| Novartis | 12 | $120 |
| Mannkind Corporation | 4 | $69 |
| BD | 3 | $59 |
| Ardelyx, Inc. | 4 | $57 |
| Abbott | 2 | $56 |
| Phathom Pharmaceuticals, Inc. | 4 | $56 |
| Boehringer Ingelheim | 2 | $42 |
| AstraZeneca | 2 | $40 |
| Pfizer | 2 | $31 |
| Exact Sciences | 1 | $27 |
| Optinose US, Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Agile Therapeutics, Inc. | 1 | $15 |
| VBI Vaccine (delaware) Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 2 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$243
- Korlym$225
- RECORLEV$150
- UBRELVY$124
- MOUNJARO$122
- ABILIFY ASIMTUFII$122
- ABILIFY MAINTENA$122
- REXULTI$119
- XARELTO$108
How this compares
$6,035 in reported general payments places this provider in the 95th percentile of 6,006 emergency medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 15 | $310 |
Paid to pharmacies, not to this prescriber.
Other emergency medicine in Sanger
- Michael BlueLone Pine$915K
- Andrew AccardiEncinitas$383K
- Fredrick Melik-AbrahamianSylmar$354K
- Graham WalkerStanford$309K
- Douglas WhiteOakland$220K
- Paul PearigenSan Diego$208K
- Richard KozakMission Viejo$203K
- Oron FrenkelSan Francisco$201K
- Matthew KaplanMission Viejo$195K
- John LiboonPoway$188K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.